Is vemurafenib FDA-approved?
On August 17, 2011, the U.S. Food and Drug Administration (FDA) approved vemurafenib tablets (Zelboraf, Hoffmann-LaRoche Inc.) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation as detected by an FDA-approved test.
Is vemurafenib an immunotherapy?
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res.
What is V600E mutation?
From Wikipedia, the free encyclopedia. V600E is a mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at amino acid 600.
Who owns Avelumab?
Avelumab was developed by Merck KGaA and Pfizer.
Is Larotrectinib chemotherapy?
VITRAKVI® is an oral medicine that is not a chemotherapy.
How effective is vemurafenib?
Vemurafenib has prolonged efficacy in patients with BRAF V600–mutant NSCLC (n = 62), as demonstrated by a 37% overall response rate. Response rates were similar in previously treated and untreated patients.
What is BRAF positive?
A BRAF mutation is a change in a BRAF gene. That change in the gene can lead to an alteration in a protein that regulates cell growth that could allow the melanoma to grow more aggressively. Approximately half of melanomas carry this mutation and are referred to as mutated, or BRAF positive.
What is the IC50 of PLX4720?
PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1 (Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf. Nature, 2013, 6;498 (7452):109-12.
What is the mechanism of action of PLX 4720?
PLX-4720 is a pyrrolopyridine that is vemurafenib in which the p-chlorophenyl group has been replaced by chlorine. It is a potent and selective inhibitor of the Raf kinase B-Raf (V600E). It has a role as a B-Raf inhibitor and an antineoplastic agent.
What is the difference between PLX4032 and BAY43-9006?
PLX4032 (Vemurafenib) is a V600 mutant B-Raf inhibitor approved by the FDA for the treatment of late-stage melanoma. Unlike BAY43-9006, which inhibits the inactive form of the kinase domain, Vemurafenib inhibits the active “DFG-in” form of the kinase, firmly anchoring itself in the ATP-binding site.
